Publications by authors named "Lara Maria Waidele"
Front Pharmacol
June 2022
Article Synopsis
- Zapnometinib, a MEK inhibitor, is being tested as a treatment for acute viral infections like COVID-19 and influenza, but more data on its pharmacodynamics (PD) and pharmacokinetics (PK) is needed.
- In studies with various species (mice, hamsters, dogs, and humans), zapnometinib reached maximum plasma concentrations 2-4 hours after administration, with elimination half-lives ranging from 4-19 hours depending on the species.
- Effective MEK inhibition (up to 80%) was observed across species, and maintaining a target plasma concentration of at least 10 μg/ml is recommended for future clinical trials due to its sustained effects.
